BioCentury
ARTICLE | Clinical News

Gelsolin recombinant actin-severing protein: Phase I trial in the U.K.

October 21, 1996 7:00 AM UTC

Biogen Inc. (BGEN), Cambridge, Mass. Product: Gelsolin recombinant actin-severing protein Indication: Respiratory diseases Status: BGEN began a Phase I trial in the U.K. in healthy volunteers. Gelsoli...